SBIR/STTR Research Award

Develop a new cisplatin based drug combination with reduced ototoxicity

Award identifier bcefea42a1bb61704a9b4fdb5149edc8ddf112aa9a89daa7071b4edaa8f90d64Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,700

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GATEWAY BIOTECHNOLOGY, INC.
Proposal award date
2017-07-05
Contract end date
2018-01-31
UEI
XDDXGL6JRRD9
Solicitation number
PA16-303
Topic code
NIDCD

Research abstract

PROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate several other signaling pathways A variety of agents mainly based on their antioxidant properties have been tested against cisplatin induced ototoxicity However many of them show limited efficacies and also interfere with the therapeutic effect of cisplatin Extensive in vitro studies have indicated that flunarizine Sibelium a drug that blocks T type calcium channels can protect cochlear cells against cisplatin induced cytotoxicity This drug also has strong anti tumor activities that act synergistically on several important aspects of cancer treatment Our preliminary studies have found that flunarizine can synergistically induce cell death with cisplatin in one lung cancer cell line and it can also protect noise induced hearing loss Based on these findings we propose to develop a new cancer drug combination by testing whether flunarizine can synergistically induce cancer cell death with cisplatin and at the same time prevent cisplatin induced ototoxicity Because lung cancer is the leading cause of cancer related death globally and cisplatin is widely used to treat this disease here we will first determine the cytotoxic effects of flunarizine and cisplatin in two lung cancer cell lines A and H and determine whether flunarizine and cisplatin have synergistic effects in these cancer cells when used in combination Aim We will then determine whether flunarizine can prevent cisplatin induced ototoxicity in vivo Aim In short based on previous studies and our preliminary data our project goal is to repurpose flunarizine to combine with cisplatin against solid tumors with a focus on lung cancer This project will generate data important to complete an Investigational New Drug IND enabling data package for future clinical studies The ultimate goal is to develop an effective cancer drug combination with fewer side effects Public Health Relevance Narrative Platinum based drugs such as cisplatin are still widely used to treat solid tumors with limited efficacies and serious side effects Our method has the potential to reduce the serious side effect of ototoxicity and increase the efficacy of cisplatin by introducing a novel drug combination

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $6,645,112. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.